Nectar Life Sciences Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Nectar Life Sciences Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $13.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Nectar Life Sciences Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $13.3M Trade | TransData Nexus

Nectar Life Sciences Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $13.3M Total Trade · DGFT Verified

Nectar Life Sciences Limited is an Indian pharmaceutical exporter with a total trade value of $13.3M across 3 products in 1 therapeutic categories. Based on 419 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftriaxone ($4.9M), Cefixime ($4.4M), Cefuroxime ($4.0M).

Nectar Life Sciences Limited — Export Portfolio & Destination Treemap

Nectar Life Sciences Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Nectar Life Sciences Limited? — Company Overview & Market Position

Nectar Life Sciences Limited, established on June 27, 1995, is a prominent Indian pharmaceutical company specializing in the production and export of finished pharmaceutical formulations, particularly cephalosporins. Headquartered in Chandigarh, India, the company is publicly listed on the Bombay Stock Exchange (BSE) under the ticker symbol 532649 and on the National Stock Exchange of India (NSE) as NECLIFE. As of March 13, 2026, the company's stock was trading at ₹11.09 per share. The authorized capital stands at ₹35.00 crore, with a paid-up capital of ₹22.43 crore. The company employs approximately 1,786 individuals. Nectar Life Sciences Limited's website is neclife.com.

What Does Nectar Life Sciences Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ceftriaxone$4.9M 2Cefixime$4.4M

Product Portfolio — Top 3 by Export Value

Nectar Life Sciences Limited exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ceftriaxone	Advanced Antibiotics	$4.9M	115	1.7%	13
2	Cefixime	Advanced Antibiotics	$4.4M	184	2.5%	8
3	Cefuroxime	Advanced Antibiotics	$4.0M	120	3.1%	6

Nectar Life Sciences Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $13.3M. The top category is Advanced Antibiotics (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Nectar Life Sciences Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Nectar Life Sciences Limited operates 13 state-of-the-art manufacturing facilities across India, strategically located in the Punjab region and Himachal Pradesh. These facilities are dedicated to the production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), including tablets, capsules, dry powder oral suspensions, granules, and injectables. The company's manufacturing units are compliant with global cGMP standards, ensuring high-quality production processes.

3Key Leadership

The leadership team at Nectar Life Sciences Limited comprises seasoned professionals with extensive experience in the pharmaceutical industry. Amit Chadah serves as the Chief Executive Officer (CEO), overseeing the company's strategic direction and operations. Sushil Kapoor holds the position of Chief Financial Officer (CFO), responsible for managing the company's financial strategies and performance. Other key executives include Sanjiv Goyal, the Managing Director, and Vikas Vij, the Chief Operating Officer (COO), who play pivotal roles in the company's management and operational efficiency.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Nectar Life Sciences Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Nectar Life Sciences Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its cephalosporin formulations from various regulatory bodies, facilitating market access in these regions. While specific details of regulatory filings and approvals are not publicly disclosed, the company's adherence to global cGMP standards and its extensive export activities indicate compliance with the stringent requirements of these markets.

2Emerging Markets

Nectar Life Sciences Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality and compliance with international standards has enabled it to penetrate these regions effectively. While specific details regarding WHO prequalification are not publicly available, the company's adherence to global cGMP standards suggests a focus on meeting international quality benchmarks, which is crucial for accessing these markets.

3Geographic Strategy

Nectar Life Sciences Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Nectar Life Sciences Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has obtained approvals for its cephalosporin formulations, facilitating market access in the U.S. While specific details of FDA inspections and observations are not publicly disclosed, the company's adherence to global cGMP standards and its extensive export activities indicate compliance with FDA requirements.

2WHO & EU GMP

Nectar Life Sciences Limited's manufacturing facilities are compliant with global cGMP standards, ensuring the production of high-quality pharmaceutical products. While specific certifications such as WHO prequalification and EU GMP are not publicly disclosed, the company's adherence to international quality standards suggests a focus on meeting the stringent requirements of these regulatory bodies.

3CDSCO & Indian Regulatory

Nectar Life Sciences Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Nectar Life Sciences Limited operates in the competitive cephalosporin segment of the global antibiotic market. Key competitors include established pharmaceutical companies with a strong presence in cephalosporin production and export. While specific market share comparisons are not publicly available, Nectar's focus on high-quality manufacturing and adherence to international standards position it as a competitive player in this segment.

2Key Differentiators

Nectar Life Sciences Limited's key differentiators include its extensive experience in cephalosporin production, adherence to global cGMP standards, and a diversified export portfolio across multiple international markets. The company's commitment to quality and compliance with international regulatory standards enhances its competitive advantage in the pharmaceutical industry.

3Strategic Position

Nectar Life Sciences Limited's strategic direction focuses on the production and export of cephalosporin formulations, a critical segment in the global antibiotic market. The company's adherence to global cGMP standards and its diversified export portfolio position it to leverage growth opportunities in both regulated and emerging markets. Future outlooks suggest continued expansion and strengthening of its global presence.

Buyer Due Diligence Brief — Evaluating Nectar Life Sciences Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Nectar Life Sciences Limited has a strong track record in the pharmaceutical industry, with a diversified export portfolio and a commitment to quality manufacturing. The company's adherence to global cGMP standards and its compliance with international regulatory requirements indicate reliability and consistency in its operations. These factors make Nectar a dependable supplier for pharmaceutical products.

2Certifications to Verify

Importers should verify the following certifications when considering Nectar Life Sciences Limited as a supplier:

FDA Registration: Confirm the registration of manufacturing facilities with the U.S. Food and Drug Administration.

WHO Prequalification: Verify the WHO prequalification status of the company's products.

EU GMP Certification: Ensure the manufacturing facilities hold EU GMP certificates.

Frequently Asked Questions — Nectar Life Sciences Limited

How many pharmaceutical products does Nectar Life Sciences Limited export from India?

Nectar Life Sciences Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Ceftriaxone ($4.9M), Cefixime ($4.4M), Cefuroxime ($4.0M). Total export value is $13.3M.

What is Nectar Life Sciences Limited's total pharmaceutical export value?

Nectar Life Sciences Limited's total pharmaceutical export value is $13.3M, based on 419 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Nectar Life Sciences Limited cover?

Nectar Life Sciences Limited exports across 1 therapeutic categories. The largest are Advanced Antibiotics (100.0%, 3 products).

Get Full Nectar Life Sciences Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.